Skip to content
QURE·Nasdaq·US

uniQure

uniQure is a gene therapy company developing single-treatment, potentially curative therapies for patients with rare and other devastating diseases, including clinical-stage candidates for Huntington's disease, refractory mesial temporal lobe epilepsy, Fabry disease, and SOD1-ALS. It also has a commercialized gene therapy, HEMGENIX, for hemophilia B, licensed globally to CSL Behring, and competes with large pharmaceutical and biotechnology companies as well as academic and research institutions developing similar therapies.

Source: SEC 10-K Mar 2, 2026

Recent Activity

Updated Oct 3, 2026
–uniQure released four-year clinical trial data for AMT-130, its experimental gene therapy for Huntington's disease.

Past updates are part of the Pro plan.

Thematic Position

QURE

Relationship Groups

Licensing1
Competitors20

Relationship details are part of the Pro plan.

Ended Relationships

7 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

tariffexport controlarmed conflict
Tariffs, export controls and reciprocal foreign tariffs affecting cross-border operations
SEC 10-KMar 2, 2026

The full regulatory passage is part of the Pro plan.

5 more · Regulatory and geopolitical insights are part of the Pro plan.